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Introduction
Systemic vasculitis is a heterogeneous group of disorders characterized by inflammation andnecrosis
in the vessel wall. The diagnosis of a systemic vasculitis is challenging, because patients usually
present a broad spectrum of manifestations that vary according to the predominant size of vessels
affected, organs and systems involved, and the extent of the inflammatory process (1). In systemic
vasculitis, disease manifestations usually cluster into clinical phenotypes and definite diagnosis rely
on confirmation by tissue biopsy, angiography, or by serologic tests. However, when a systemic
vasculitis is under investigation, it is of paramount importance to keep in mind vasculitis mimics
(e.g., genetic vascular disorders and atheroembolic diseases) and secondary causes (i.e., infections,
malignancy, connective tissue disorders, or drugs) (2).
The main serologic tests for the diagnosis of primary systemic vasculitides are antineutrophil
cytoplasmic antibodies (ANCA), cryoglobulins, anti-glomerular basement membrane (anti-GBM)
antibodies, and anti-C1q antibodies (3). Although, several other autoantibodies have been investi-
gated in systemic vasculitis, the clinical usefulness of these antibodies still needs further investigation
(1, 2) (Table 1). Herein, themain autoantibodies and their clinical associations in systemic vasculitis
are reviewed.
Antineutrophil Cytoplasmic Antibodies
Antineutrophil cytoplasmic antibodies are the diagnostic biomarkers for some small-vessel necrotiz-
ing vasculitis such as granulomatosis with polyangiitis (GPA) (formerly Wegener’s granulomatosis),
mycroscopic polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis (EGPA) (formerly
Churg–Strauss syndrome), and renal limited vasculitis (RLV). The main target antigens of ANCA
are proteinase 3 (PR3) and myeloperoxidase (MPO) located on primary granules of neutrophils
and lysosomes of monocytes. ANCA reactivity is variable and differences in affinity of ANCA with
PR3 antigen have been described with a higher inhibition of PR3 activity observed in GPA patients
in remission compared with those with active disease. Unlike, PR3-ANCA, myeloperoxidase-
antineutrophil cytoplasmic antibodies (MPO-ANCA) recognize a restricted number of epitopes
in MPO and do not impair its enzymatic activity. When ANCA bind to their target antigen, they
activate neutrophils and induce the release of granule enzymes, pro-inflammatory cytokines, and
the generation of respiratory burst, leading to endothelial damage and eventually to the vasculitic
process (4).
Currently, the main assays for the detection of ANCA in sera are indirect immunofluorescence
(IIF) on ethanol-fixed human neutrophils and enzyme-linked immunosorbent assay (ELISA) for
antigen specificity. The International Consensus Statement on Testing and Reporting ANCA rec-
ommends the combination of both techniques (IIF and ELISA) for the detection of ANCA in
patients under investigation for ANCA-associated vasculitis, since 10% of ANCA positive GPA
or MPA patients present only IIF positive results (5). The main patterns observed in IIF are
the cytoplasmic (C-ANCA) pattern that displays a diffuse granular cytoplasmic staining with
interlobular accentuation and the perinuclear (P-ANCA) pattern that shows perinuclear fluores-
cence with nuclear extension. C-ANCA is mostly associated with anti-PR3 antibodies, whereas
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TABLE 1 | Autoantibodies in primary systemic vasculitides.
Vasculitis Autoantibodies
Takayasu arteritis AECA
Anti-aorta antibodies
Anti-ferritin antibodies
Anti-annexin V antibodies
Anti-monocyte antibodies
Giant cell arteritis AECA
Anti-ferritin antibodies
Polyarteritis nodosa AECA
Kawasaki disease AECA
ANCA-associated vasculitis AECA
PR3-ANCA
MPO-ANCA
Anti-LAMP-2 antibodies
Immune complex vasculitis Anti-C1q antibodies
Anti-GBM antibodies
Cryoglobulins
IgA-ANCA
Rheumatoid factor
AECA, antiendothelial cell antibodies; ANCA, antineutrophil cytoplasmic antibodies; GBM,
glomerular basement membrane; LAMP-2, lysosome associated membrane protein-2;
MPO, myeloperoxidase; PR3, proteinase 3.
P-ANCA is associated with anti-MPO antibodies. Another ANCA
pattern described is the atypical ANCA, also referred as A-ANCA.
A-ANCA usually shows perinuclear staining without nuclear
extension, or diffuse flat cytoplasmic staining, or the combina-
tion of both cytoplasmic and nuclear/perinuclear staining on
neutrophils (5, 6).
Antineutrophil cytoplasmic antibodies are positive in up to
90% of patients with active generalized GPA, while only 40%
of patients with localized disease present a positive ANCA test.
PR3-ANCA is found in up to 90% of GPA patients with a pos-
itive ANCA. The presence of MPO-ANCA is observed in MPA,
EGPA, and with RLV with a rate of positivity of 70, 50, and 80%,
respectively. The combination of IIF and ELISA for PR3-ANCA
or MPO-ANCA yields a specificity of 99% (4). ANCA specificity
in ANCA-associated vasculitis is more closely related to disease
phenotype rather than clinical diagnosis. Patients presenting renal
involvement and small-vessel vasculitis without evidence of gran-
ulomatous inflammation are more likely to have MPO-ANCA,
whereas PR3-ANCA is more associated with necrotizing granulo-
matous inflammation and more frequent relapses compared with
MPO-ANCA. Moreover, results from a genome wide association
study that evaluated HLA and SERPINA1 genes showed that
genetic background in ANCA-associated vasculitis is related with
ANCA-specificity rather than with disease phenotype. ANCA
levels often fluctuate following disease activity, but they are not
meant to guide therapeutic decisions (7).
Myeloperoxidase-antineutrophil cytoplasmic antibodies are
also found in 30%of patients with anti-GBMdisease (4). A-ANCA
is associated with antibodies against other target antigens in cyto-
plasmic granules of neutrophils such as lactoferrin, lysozyme,
azurocidin, elastase, cathepsin G, and bactericidal/permeability
increasing enzyme (BPI) (8). A-ANCA may be found in inflam-
matory bowel disease, mostly ulcerative colitis, autoimmune hep-
atitis, primary sclerosing cholangitis, rheumatoid arthritis, and
drug exposure or drug-inducedANCA-associated vasculitis (6, 8).
During the last few years, different immunoassays have been
developed for the detection of ANCA including second and third
generation ELISA tests, automated systems for analyzing fluo-
rescence patterns, chemiluminescent immunoassays, lateral flow
assay systems, and bead-based multiplex assays (6–8). The first
generation ELISA used to detect PR3-ANCA and MPO-ANCA
applies absorption coating methods with target antigens directly
immobilized to the surface of the plate what induces masking
and deformation of epitopes. This direct ELISA has significant
variation amongst kits and lacks sensitivity (6, 7). Second and
third generation ELISA tests were developed to improve sensi-
tivity. The second generation ELISA is also referred as capture
ELISA and uses capture molecules, mostly monoclonal antibod-
ies to bind the target antigen to the plate surface, while the
third generation ELISA uses anchor molecules to immobilize
the antigen to the plate surface. A study that compared three
generations of PR3-ANCA assays found the highest sensitiv-
ity with the third generation anchor ELISA: 96.0% [95% confi-
dence interval (CI): 79.6–99.3%], followed by IIF: 92.0% (95% CI:
73.9–98.8%), by second generation capture ELISA: 72.0% (95%
CI: 50.6–87.9%), and by first generation direct ELISA: 60.0% (95%
CI: 38.7–78.8%) (9).
Despite advances in assays to detect ANCA, to date the com-
bination of IIF with the ELISA test to detect ANCA specificity
is still recommended, preferably with second or third generation
ELISA. Although, chemiluminescent immunoassay has similar or
superior diagnosis performance for ANCA-associated vasculitis
compared to conventional assays, the role of novel techniques to
detect ANCA deserves further studies (7, 8).
Anti-Lysosome Associated Membrane
Protein-2 Antibodies
The lysosome associated membrane protein-2 (LAMP-2) is a
heavily glycosilated protein present in lysosomes, but it also traf-
fics to the cell surface where it is expressed by monocytes, neu-
trophils, and endothelial cells. Moreover, LAMP-2 may be also
found within the membrane of MPO/PR3 intracellular vesicles
of neutrophils. Thus, anti-LAMP-2 antibodies are considered a
subtype of ANCA. The pathogenicity of anti-LAMP-2 antibodies
is highlighted by the striking 100% homology observed between
the epitope P41–49 of LAMP-2 and a sequence in FimH, a bac-
terial adhesin present in fimbriated bacterial such as Escherichia
coli (10).
Anti-LAMP-2 antibodies were firstly described in 87% of
patients with RLV and this high prevalence of anti-LAMP-2 anti-
bodies was further confirmed in amulticenter study that included
patients with ANCA-associated vasculitis (i.e., GPA, MPA, and
RLV) at disease presentation from Austria, the Netherlands, and
from the United Kingdomwith a positivity of 89%, 91%, and 80%,
respectively. In contrast, anti-LAMP-2 antibodies were detected
in only 7% of patients in remission. However, the prevalence of
anti-LAMP-2 antibodies was only 21% in patients with ANCA-
associated vasculitis from a study performed in North Carolina.
The reasons for these controversial results are probably due to
different methods used to detect anti-LAMP-2 antibodies in both
studies and to the inclusion of patients in different phases of the
disease (e.g., active and quiescent disease) in the latter study (10).
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Cryoglobulins
Cryoglobulins are typically immunoglobulins that precipitate
in vitro at temperatures <37°C and solubilize upon re-warming.
Cryoglobulinemia refers to the presence of cryoglobulins in
patient’s serum. Besides the quantification of circulating cryo-
globulins, it is also necessary to analyze the nature of circulat-
ing cryoglobulins (11). Brouet classification is the most frequent
way of classifying cryoglobulins, this classification relies on the
clonality of immunoglobulins and on rheumatoid factor activity.
Type I cryoglobulinemia refers to the presence of monoclonal
immunoglobulin, including IgM, IgG, IgA, or light chains (e.g.,
kappa or lambda) without rheumatoid factor activity. Type I cryo-
globulinemia is usually associated with hematologic malignancies
(e.g., Waldenström macroglobulinemia or multiple myeloma).
Type II cryoglobulinemia is typically defined as the presence
of polyclonal immunoglobulins associated with a monoclonal
IgM with rheumatoid factor activity. Type III cryoglogulinemia
is a mixture of polyclonal IgM and IgG. Both type II and III
are referred as mixed cryoglobulinemia and are associated with
chronic viral infections, mainly hepatitis C virus (HCV) and
connective tissue diseases. In the latter group of diseases, cryo-
globulins are a mixture of autoantibodies that become antigenic.
The distinction between those autoantibodies and autoantigens
is rather difficult. No other cause may be found in up to 10%
of patients with mixed cryoglobulinemia and those cases are
regarded as essential cryoglobulinemia (12).
Two clinical syndromes are recognized as caused by circu-
lating cryoglobulins in serum: the hyperviscosity syndrome and
cryoglobulinemic vasculitis. Although most patients with type I
cryoglobulinemia are asymptomatic, the hyperviscosity syndrome
is the main set of manifestations in this type of cryoglobuline-
mia and includes Raynaud’s phenomenon, digital ischemia, renal
failure, vision blurring, loss of vision, headache, vertigo, nystag-
mus, deafness, confusion, coma, and other neurological mani-
festations (12). Cryoglobulinemic vasculitis usually develops in
patients with type II and III cryoglobulinemia and is manifested
by palpable purpura, livedo reticularis, Raynaud’s phenomenon,
arthralgia,myalgias, glomerulonephritis, and peripheral neuropa-
thy. In severe cases, patients present rapidly progressive glomeru-
lonephritis, central nervous system vasculitis and/or pulmonary
vasculitis (11).
Anti-Glomerular Basement Membrane
Antibodies
Anti-glomerular basement membrane antibodies are biomarkers
for the diagnosis of anti-GBM antibody disease (formerly Good-
pasture’s syndrome), which has been recently classified as immune
complex small-vessel vasculitis affecting glomerular and/or pul-
monary capillaries. Renal involvement is due to crescentic
glomerulonephritis and is usually manifested as rapidly progres-
sive glomerulonephritis, whereas typical pulmonary involvement
is pulmonary hemorrhage (3).
Anti-glomerular basement membrane antibodies may be
detected by direct IF on renal biopsy, where a linear deposition
of IgG is observed on glomerular capillaries. Alternatively, when
renal biopsy cannot be performed the ELISA test is used to detect
circulating anti-GBM antibodies in patients with active disease
and its sensitivity ranges from 65 to 100%. ELISA assays that
use purified or recombinant alpha-3 chain of collagen IV present
the best sensitivity. Antigen specificity may also be confirmed by
Western blot. IIF is rarely performed (13).
Anti-C1q Antibodies
Anti-C1q antibodies are biomarkers for the diagnosis of
hypocomplementemic urticarial vasculitis (HUV). This entity
has recently been classified as immune complex small-vessel
vasculitis by 2012 Chapel Hill Consensus Conference. Common
features of HUV include glomerulonephritis, cutaneous lesions
(e.g., wheals that persist for more than 24 h), arthralgia or
arthritis, lung involvement, gastrointestinal vasculitis, and ocular
inflammation (3).
Other Autoantibodies
Anti-endothelial cell antibodies (AECA) are a heterogeneous fam-
ily of antibodies with multiple target antigens on endothelial
cell membrane. AECA have been described in several primary
systemic vasculitides such as Takayasu arteritis, giant cell arteritis,
polyarteritis nodosa, GPA, MPA, EGPA, IgA vasculitis, Kawasaki
disease, and Behçet’s disease. However, the usefulness of AECA in
clinical practice has still to be determined (14).
Anti-ferritin antibodies are novel IgG autoantibodies against
human ferritin heavy chain and its terminal N peptide. Using the
combination of results from different ELISA assays, anti-ferritin
antibodies have been described in up to 92% of patients with
giant cell arteritis/polymyalgia rheumatica and in 62%ofTakayasu
arteritis patients. However, anti-ferritin antibodies are also found
in 28% of patients with systemic lupus erythematosus, in 22%
of patients with febrile illnesses, and in 11% of patients with
atherosclerotic disease, but not in healthy blood donors (15).
Concluding Remarks
To date, the investigation of circulating autoantibodies has been
shown to be useful for diagnosis of systemic small vessel vasculi-
tis including ANCA-associated vasculitis and immune complex
vasculitis. No specific autoantibody has been shown to be of any
help in diagnosis or in evaluating disease activity in patients with
medium and large vessel vasculitis.
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